Download our whitepaper,
"The Road to Osteoarthritis Drug Approval: Lessons from Successes and Failures"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Osteoarthritis Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Osteoarthritis.
- Comprehensive Analysis of FDA-Approved Osteoarthritis Drugs.
- How Diagnostic Criteria for Osteoarthritis Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Osteoarthritis Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Osteoarthritis
Osteoarthritis (OA) is a chronic, degenerative joint disease and a leading cause of disability worldwide, impacting over 500 million people globally.
This whitepaper explores the complex interplay of mechanical, biological, and genetic factors underlying OA, emphasizing the multifaceted nature of the disease. It delves into current trends, including the rising prevalence driven by aging populations and lifestyle shifts, while highlighting advancements in diagnostics, treatment strategies, and emerging therapies.
At iNGENū, we are dedicated to advancing the understanding and treatment of Osteoarthritis. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted.
Osteoarthritis affects approximately
7%
of the world's population
Around
32.5
million adults in the US have Osteoarthritis
Osteoarthritis affects up to
50%
of individuals over the age of 60
Our clinical team has over
120
years of combined clinical trial experience